Concepedia

Katalin Csermak

KC

Statistics

Publications

6

Citations

461

H-Index

6

Active since

2000

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Novartis (India)

Infectious Diseases Research Collaboration

University of Bamako

Katalin Csermak is an author at Novartis (Switzerland) specializing in drug discovery, medicine, and pharmacology.

Top concepts

Publications per year

2000–2023

6

Publications

6

PKC412--a protein kinase inhibitor with a broad therapeutic potential.

D Fabbro, Stephan Ruetz, Stephan Bodis et al. · PubMed · 2000 · 270 citations

, , +17

Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.

K. Ganeshaguru, R G Wickremasinghe, Dylan T. Jones et al. · PubMed · 2002 · 52 citations

A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C

Andres Virchis, K. Ganeshaguru, Dylan T. Jones et al. · The Hematology Journal · 2002 · 39 citations

, , +8

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial

Bernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa et al. · The Lancet Infectious Diseases · 2023 · 36 citations

, , +3

Estimated distribution of malaria cases among children in sub-Saharan Africa by specified age categories using data from the Global Burden of Diseases 2019

Olorunfemi A. Oshagbemi, Pedro López‐Romero, Cornelis Winnips et al. · Malaria Journal · 2023 · 35 citations · Full text

1–5 of 6